What Investors Really Want to See in a Medtech Series A Fundraising Strategy

Every medtech Series A fundraising strategy I've watched close cleanly starts from the same place. A strong medtech Series A fundraising strategy is not a pitch document.

It is the sum of market engineering work done in the 18 months before a single investor meeting. Medtech Series A investors have watched hundreds of clinically validated devices stall in the traction gap between FDA clearance and commercial adoption.

They know the failure mode on sight. So they underwrite the market engineering, not the deck.

Over 370-plus episodes of State of MedTech, the pattern is consistent.

Teams that raise Series A cleanly bring evidence of repeatable demand, a specific market narrative, and named customers. Companies that stall bring TAM slides and financial projections that fall apart the moment a partner asks a second question.

Takeaways

• A medtech Series A fundraising strategy that closes is not a pitch deck. It is a market engineering system that shows investors repeatable, measurable demand before the round opens.
• Medtech Series A investors have stopped underwriting TAM slides. They underwrite named customers, real commercial traction, and evidence the market was engineered before clearance.
• FDA clearance is the starting line, not the finish line. Clinical validation ≠ commercial traction, and the traction gap is what separates funded medtech Series A rounds from stalled ones.
• The founders raising cleanly at Series A predicted the future and then made it happen. That prediction discipline is what a public-company CEO does every quarter, and it starts before Series A.
• Great companies don't wait for markets to form. They engineer them, which is why the market narrative you bring to the room matters more than any single financial projection.

Why Traction Is Repeatable Measurable Demand

That reframe came from an episode about how market engineering helps medtech startups raise capital:

"Traction, believe it or not, it's not revenue or product launch or clinical milestones, okay? The way you want to think about traction is that it's repeatable, measurable demand."

That reframe alone changes how a Series A conversation opens.

Most pre-revenue medtech founders bring milestone charts into the pitch. Clearance date, first-in-human date, pivotal trial enrollment. Those matter internally.

Series A investors sitting across the table have seen thousands of milestone charts. What they haven't seen from the founder yet is whether the market repeatedly, measurably wants what the company is building.

Repeatable, measurable demand looks concrete.

Physicians requesting demos on their own initiative. Health systems inbound about pilots. Patient inquiries growing month over month. Whitespace inside a category that competitors haven't defined, where founder-led content is pulling that whitespace into the founder's orbit.

That's the traction question at Series A. Not "how big is the market" but "how do we know the market wants this."

Medtech Series A Investors Have Stopped Asking About TAM

This shift came up in an episode about the $100B shift reshaping medtech markets:

"Don't tell us about the TAM. We're not interested. Who's going to buy this? How many people have you talked to already? What's the commercial traction look like for this thing once you hit the regulatory milestones?"

Read that as the actual scoring criteria at Series A.

Investors have moved past the TAM slide. It's the section they've watched founders overwork for the last decade, and it consistently fails to predict which companies eventually get to commercial scale.

The questions replacing it are direct.

Who is going to buy this?

How many named potential customers have you talked to already?

What does the commercial evidence look like the moment clearance lands?

A medtech Series A fundraising strategy that opens with a TAM slide is answering a question the room stopped asking two years ago. A strategy that opens with the answer to those three specific questions is answering the one the room is really holding.

That's the market-product fit test at fundraising. You're not pitching to a generic Series A fund. You're pitching to a specific set of investors whose diligence process is asking those three questions in that order, and the pitch has to be tuned to that reality.

The Prediction Discipline Public CEOs Have and Pre-Series-A Founders Need

I made this exact point in an episode about medtech fundraising valuation and investor strategy:

"You're essentially proving the investor that what you say is going to happen ends up happening. The skill set of being a public CEO is that you have to predict the future and then you have to make it happen."

That skill set doesn't start after IPO. It starts at Series A.

Medtech Series A investors are pricing whether this founder can hold to a plan across five- to seven-year cycles of clinical setbacks, reimbursement delays, and hospital adoption cycles that always run longer than the founder projected.

The way they underwrite that risk is by looking at whether earlier commitments held.

If a founder said in the seed round that clearance would land in Q3, and clearance did land in Q3, the Series A pitch starts from a completely different position than a founder whose earlier commitments slipped by a year.

The pattern of hitting stated milestones on stated timelines matters more at Series A than the size of any single milestone.

Founders who show up at Series A with a track record of predicted-and-delivered milestones are proving the underwriting question themselves, before the investor has to ask it.

That's the deep signal medtech Series A investors are looking for.

Public-company CEOs do this quarter after quarter with earnings guidance. Pre-Series-A medtech founders do it milestone after milestone, and Series A is where the pattern finally gets underwritten.

Great Companies Engineer Markets Before They Launch

That principle is the whole thesis behind an episode about barbarians beating bureaucrats in hardball market strategy:

"Markets don't form after launch. They form before it. And in medtech, they don't just form on their own. They have to be crafted and engineered. Nobody finds you in medtech. You engineer being found."

Great companies don't wait for markets to form. They engineer them.

Every funded medtech Series A round I've covered on the show started with a founder who was building market visibility 12 to 18 months before the round opened.

Podcast appearances. Bylined pieces in the trade press. A specific LinkedIn point of view compounded over dozens of posts.

By the time the round opened, the investor community already had a read on the founder, the category, and the market position. The deck was the finishing artifact. It wasn't the piece that had to persuade anyone.

The teams that wait to fundraise before they engineer the market are pitching to investors who have no prior context and only a deck to price against.

That pitch usually stalls. The companies that engineer the market first are pitching to investors who already track the category, and the deck becomes an extension of the position the founder built.

That's the market engineering discipline at the Series A layer. It's the same one that determines who gets to Series B on reasonable terms, and it starts before the first meeting.

What This Means for Medtech Founders

Every medtech Series A round that closed cleanly on the show followed the same underlying pattern.

Repeatable, measurable demand established before the round opened. TAM slides removed from the deck.

A track record of hitting stated milestones on stated timelines. A market position engineered publicly across the 18 months before the pitch.

A medtech Series A fundraising strategy built around those four inputs closes rounds. A strategy built around a polished deck alone rarely does.

This is the same discipline behind the medtech investor pitch that closes at Series A. The pitch is downstream of the market engineering, not a substitute for it.

So the Series A question isn't how sharp your deck is. It's whether the market can repeat your category thesis without you in the room.

If yes, the round prices on demand signal you already built. If no, the round prices on projections investors have discounted for a decade.

That's what we built MarketCraft to solve. It's a market engineering practice that runs upstream of the Series A conversation so investors underwrite a demand signal you already engineered.

The fundraising strategy is the sum of a specific market narrative, repeatable demand, and a public track record of predicted milestones landing on time. The pitch itself becomes the smallest part of the total work.

Frequently Asked Questions

What Do Medtech Series A Investors Really Underwrite?

Medtech Series A investors underwrite repeatable, measurable demand, a founder's ability to hit stated milestones on stated timelines, and the market engineering work done before the round opened.

TAM slides and financial projections carry less weight than they did five years ago. Named potential customers, physician demand, and a specific market narrative carry more.

How Long Before a Medtech Series A Should a Founder Start Engineering Market Visibility?

Twelve to 18 months minimum. Series A rounds that closed cleanly ran through target investors' feeds, trade press, and podcast queues long before the round opened. Waiting until the round is live to build public visibility means pitching to investors who have no prior context.

What Replaces the TAM Slide in a Modern Medtech Series A Deck?

Named customers, physician demand signals, health-system inbound, and a specific market narrative about which segment the founder is building the category around. Investors want to know who is going to buy the product and how the founder knows, not how big the theoretical market could become.

How Does a Medtech Founder Prove the "Predict and Deliver" Pattern at Series A?

By pointing to specific commitments made in the seed round or earlier and showing they landed on time. Clearance milestones, first-in-human dates, pivotal trial enrollment, revenue milestones. A founder with three or four stated-and-delivered commitments has the underwriting pattern Series A investors want to see.

Listen to the Full Conversations

• How Market Engineering Helps Medtech Startups Raise Capital
• This Month in Medtech: The $100B Shift Reshaping Markets
• Medtech Fundraising in 2025: Valuation, Mistakes, and Investor Strategy
• Why Barbarians Always Beat Bureaucrats: Hardball Market Strategy

Subscribe wherever you listen to podcasts.

About the Author

Omar Khateeb is the founder of MarketCraft and host of The State of MedTech, a leading podcast in the medtech industry.

He works with medtech founders and commercial leaders on market engineering, commercialization strategy, and revenue growth. Visit marketcraft.ai or subscribe to The State of MedTech for weekly conversations with the people building the future of medical devices.